Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
256 hedge funds and large institutions have $7.3B invested in Acceleron Pharma in 2021 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 83 increasing their positions, 92 reducing their positions, and 30 closing their positions.
20% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 30
5% more capital invested
Capital invested by funds: $6.92B → $7.3B (+$379M)
1% more funds holding
Funds holding: 253 → 256 (+3)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
10% less repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 92
25% less call options, than puts
Call options by funds: $33.7M | Put options by funds: $44.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$187M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$73.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$36.2M |
| 4 |
EP
Eversept Partners
New York
|
+$31.3M |
| 5 |
CG
Carmignac Gestion
Paris,
France
|
+$24.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$123M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$58.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$37M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$35.8M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$27.9M |
XLRN Hedge Fund Activity: Q1 2021 in Review
256 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q1 2021, worth a combined $7.3B — up 5.5% from $6.92B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new XLRN positions and 30 closed out — a net gain of 6 holders — while 83 added to existing stakes and 92 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $187M. The largest seller was Fidelity Investments, cutting an estimated $123M.
- 256 institutional investors held Acceleron Pharma (XLRN) as of Q1 2021, up from 253 in Q4 2020.
- Funds reported $7.3B of Acceleron Pharma stock for Q1 2021, up 5.5% quarter-over-quarter.
- 36 funds opened new Acceleron Pharma positions in Q1 2021 and 30 closed out, a net change of +6 holders.
- The largest Acceleron Pharma buyer in Q1 2021 was Avoro Capital Advisors, an estimated $187M added.
- The largest Acceleron Pharma seller in Q1 2021 was Fidelity Investments, an estimated $123M sold.
Based on aggregated 13F filings for Q1 2021.